Atossa Therapeutics to Present at the Maxim Growth Summit 2025
Atossa Therapeutics (Nasdaq: ATOS) announced that Chairman & CEO Steven Quay, M.D., Ph.D. will present at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel, New York City.
The company invited new and existing investors to attend or request one-on-one meetings to discuss Atossa's clinical programs, development plans, and capital-allocation strategy focused on preparing data packages for potential regulatory submissions and commercialization.
Investors are directed to the Atossa investor website for presentations, SEC filings, FAQs, and meeting requests.
Atossa Therapeutics (Nasdaq: ATOS) ha annunciato che il presidente e CEO Steven Quay, M.D., Ph.D., terrà una presentazione al Maxim Growth Summit il 22-23 ottobre 2025 presso l'Hard Rock Hotel di New York.
L'azienda invita investitori nuovi ed esistenti a partecipare o a richiedere incontri individuali per discutere i programmi clinici di Atossa, i piani di sviluppo e la strategia di allocazione del capitale focalizzata sulla preparazione di pacchetti di dati per potenziali sottomissioni regolamentari e per la commercializzazione.
Gli investitori sono indirizzati al sito investitori di Atossa per presentazioni, filing SEC, FAQ e richieste di meeting.
Atossa Therapeutics (Nasdaq: ATOS) anunció que el presidente y CEO Steven Quay, M.D., Ph.D., presentará en la Maxim Growth Summit el 22-23 de octubre de 2025 en el Hard Rock Hotel de la ciudad de Nueva York.
La empresa invitó a inversores nuevos y existentes a asistir o solicitar reuniones uno a uno para discutir los programas clínicos de Atossa, sus planes de desarrollo y su estrategia de asignación de capital centrada en preparar paquetes de datos para posibles presentaciones regulatorias y la comercialización.
Los inversores deben dirigirse al sitio para inversores de Atossa para presentaciones, presentaciones SEC, preguntas frecuentes y solicitudes de reuniones.
Atossa Therapeutics (Nasdaq: ATOS)는 의장 겸 CEO인 Steven Quay, M.D., Ph.D.가 Maxim Growth Summit에서 2025년 10월 22-23일에 뉴욕시 하드 록 호텔에서 발표할 것이라고 발표했습니다.
회사는 신규 및 기존 투자자들을 초청하여 Atossa의 임상 프로그램, 개발 계획 및 자본 배분 전략에 대해 논의하기 위한 1대1 미팅 요청이나 참석을 권장했습니다. 이 전략은 잠재적 규제 제출 및 상용화를 위한 데이터 패키지 준비에 초점을 맞추고 있습니다.
투자자들은 발표, SEC 제출, 자주 묻는 질문 및 미팅 요청을 위해 Atossa 투자자 웹사이트로 안내됩니다.
Atossa Therapeutics (Nasdaq : ATOS) a annoncé que le président-directeur général Steven Quay, M.D., Ph.D., effectuera une présentation lors du Maxim Growth Summit les 22-23 octobre 2025 à l'hôtel Hard Rock de New York.
L'entreprise invite les investisseurs nouveaux et existants à assister ou à demander des entretiens individuels pour discuter des programmes cliniques d'Atossa, des plans de développement et de la stratégie d'allocation du capital axée sur la préparation de packages de données pour d'éventuelles soumissions réglementaires et la mise sur le marché.
Les investisseurs sont dirigés vers le site des investisseurs d'Atossa pour les présentations, les dépôts SEC, les FAQ et les demandes de rendez-vous.
Atossa Therapeutics (Nasdaq: ATOS) gab bekannt, dass der Vorsitzende und CEO Steven Quay, M.D., Ph.D., auf dem Maxim Growth Summit am 22.–23. Oktober 2025 im Hard Rock Hotel in New York City auftreten wird.
Das Unternehmen forderte neue und bestehende Investoren auf, an der Veranstaltung teilzunehmen oder Einzelgespräche zu beantragen, um Atossas klinische Programme, Entwicklungspläne und Kapitalallokationsstrategie zu besprechen, die darauf abzielt, Datenpakete für potenzielle regulatorische Einreichungen und die Kommerzialisierung vorzubereiten.
Investoren werden an die Atossa-Investorenseite verwiesen, wo Präsentationen, SEC-Unterlagen, FAQs und Meeting-Anfragen zu finden sind.
Atossa Therapeutics (بورصة ناسداك: ATOS) أعلنت أن رئيس مجلس الإدارة والمدير التنفيذي ستيفن كوي، دكتور في الطب، ودكتور في الفلسفة، سيقدم عرضاً في Maxim Growth Summit في 22–23 أكتوبر 2025 في فندق هارد روك، مدينة نيويورك.
دعت الشركة مستثمرين جدد وقائمين للحضور أو طلب اجتماعات فردية لمناقشة برامج Atossa السريرية وخطط التطوير واستراتيجية تخصيص رأس المال التي تركز على تجهيز حزم البيانات لطلبات تنظيمية محتملة والتسويق.
يُوجَّه المستثمرون إلى موقع Atossa للمستثمرين للحصول على العروض والتقارير SEC والأسئلة الشائعة وطلبات الاجتماعات.
Atossa Therapeutics (纳斯达克股票代码：ATOS) 董事长兼首席执行官 Steven Quay, M.D., Ph.D. 将于 2025年10月22–23日 在纽约市 Hard Rock Hotel 举行的 Maxim Growth Summit 上进行演讲。
公司邀请新老投资者出席或请求一对一会谈，以讨论 Atossa 的临床项目、开发计划和资本配置策略，专注于为潜在的监管提交和商业化准备数据包。
投资者将被引导至 Atossa 投资者网站，以获取演示文稿、SEC 文件、常见问题解答和会议请求。
- None.
- None.
Invites New Investors to Learn More About $ATOS
Why attend or follow along?
-
Clear strategy & focus: Atossa is concentrating capital on programs and data packages that can enable future regulatory submissions and potential commercialization.
-
Compelling thesis for new investors: Atossa believes the combination of disciplined capital allocation, clear clinical objectives, and a sizeable unmet need in breast cancer creates an attractive setup for long-term value creation.
- Direct access to leadership: Conference 1x1s provide an opportunity to discuss Atossa's development plans, milestones, and how the Company thinks about returns on R&D spend.
Call to Action
Prospective and existing investors are encouraged to visit Atossa website's Investors section to review latest presentations, SEC filings, and FAQs, and to sign up for email alerts. Learn more about Atossa and $ATOS at www.atossatherapeutics.com (Investors → Events & Presentations).
Note to investors: To request a 1x1 meeting at the Maxim Growth Summit or to obtain the latest investor deck, please visit www.atossatherapeutics.com (Investors) or contact CORE IR at the emails below.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative therapies for significant unmet needs in breast cancer. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. For more information, visit www.atossatherapeutics.com and refer to Atossa's filings with the
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated impact of program updates, expected study costs and timelines, operating runway, capital allocation, and plans for NDA-enabling activities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, without limitation, clinical, regulatory, operational, financial, and market risks; the possibility that study timelines or costs differ from current expectations; that clinical results may not support further development or regulatory submissions; and other risks described in Atossa's most recent periodic reports filed with the SEC, including the "Risk Factors" sections therein. Atossa undertakes no obligation to update forward-looking statements except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-to-present-at-the-maxim-growth-summit-2025-302580384.html
SOURCE Atossa Therapeutics Inc
FAQ
When and where will Atossa (NASDAQ: ATOS) present at the Maxim Growth Summit 2025?
Who from Atossa will be available for investor meetings at the Maxim Growth Summit?
How can investors request a 1x1 meeting with Atossa at the October 2025 Maxim Growth Summit?
What investor materials will Atossa make available around the Maxim Growth Summit 2025?
What topics will Atossa discuss at the Maxim Growth Summit that matter to shareholders?
